Middle East & Africa In-Vitro Diagnostic Market Size and Forecast (2021 - 2034), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Reagents and Kits, Instruments, and Software and Services), Technology (Immunoa

According to our new research study on “Middle East & Africa in-vitro diagnostic market forecast to 2034 -Regional Analysis - by Product, Technology, Application, Usability, Site of Testing, Specimen, and End User,” the market is anticipated to grow from US$ 3.89 billion in 2025 to US$ 7.24 billion by 2034; the market is expected to register a CAGR of 7.2% from 2026 to 2034. Middle East & Africa In-Vitro Diagnostic market growth is attributed to the rising prevalence of chronic noncommunicable diseases, persistent infectious disease burden, health system strengthening, and public health surveillance expansion.

Governments and international health agencies have prioritized strengthening laboratory networks to manage chronic and infectious disease challenges. PublicHO African Region’s progress reporting on noncommunicable diseases and public health indicates strong emphasis on early diagnosis and integrated care, which requires laboratory diagnostic infrastructure and standardized testing protocols to reach targets for disease control and prevention. Enhanced surveillance systems for communicable diseases, including HIV, cholera, and routine vaccine-preventable diseases, rely on diagnostic testing to inform public health responses. According to the WHO HIV/AIDS fact sheet, while at the global level 40.8 million people were living with HIV at the end of 2024, continued efforts to diagnose, treat, and suppress viral load through laboratory testing remain central to controlling the epidemic. Multi-country outbreaks of cholera in Africa and the Eastern Mediterranean stimulate investment in laboratory preparedness, rapid diagnostic test (RDT) stockpiles, and quality assurance programs to support early case detection and response planning, as documented in WHO outbreak situation reports from 2023-2024. As health systems expand coverage and surveillance sophistication, routine lab testing becomes embedded in primary care and national disease programs, increasing demand for an array of IVD products from basic clinical chemistry to advanced molecular diagnostics.

Middle East & Africa In-Vitro Diagnostic market is categorized into the Saudi Arabia, South Africa, UAE, and the Rest of Middle East & Africa. According to the International Diabetes Federation, in 2024, approximately 20.7 % of UAE adults (nearly 1.27 million people) were living with diabetes, a persistently high national prevalence that necessitates regular blood glucose and related biomarker testing. Large segments of the population are at risk of metabolic and cardiovascular complications linked to diabetes and obesity, with lifestyle risk factors such as being overweight present at elevated levels, driving demand for panel testing and monitoring. Government health authorities have responded with robust National Prediabetes and Diabetes Screening campaigns. The Ministry of Health and Prevention (MoHAP) exceeded its early-detection target by conducting over 150,000 screening tests in a year under the Government Accelerators Programme, emphasizing widespread use of HbA1c and other diagnostic assays. In addition to diabetes efforts, routine screening for infectious diseases, cardiovascular markers, cancer biomarkers, and genetic conditions are integrated into preventive care pathways, reflecting a strategic shift toward early diagnosis. The combination of high chronic disease prevalence, structured national screening initiatives, and the integration of molecular, point-of-care, and automation-enabled IVD platforms is therefore driving heightened utilization of in-vitro diagnostics across clinical settings in the UAE.

According to 2024 mid-year estimates by Statistics South Africa, approximately 8.0 million people in South Africa are living with HIV, with 12.7 % overall national prevalence and 16.68 % among adults aged 15-49, maintaining significant demand for HIV testing, monitoring, and related IVD assays. According to the World Health Organization (WHO), South Africa continues to face a high tuberculosis incidence of 427 per 100,000 population in 2023, and over half of TB patients also have HIV, reinforcing the need for combined infectious disease diagnostics, including rapid molecular tests and point-of-care screening.

Chronic non-communicable diseases such as diabetes and cardiovascular conditions are increasing, with government health data indicating that diabetes remains one of the leading causes of death and has risen as a proportion of mortality, particularly among women. This combined disease burden expands demand for biochemical and molecular diagnostics across public and private sectors. The government has prioritized early detection and prevention, strengthening national health screening programs and laboratory networks that drive IVD utilization.

Technological advancements such as PCR, next-generation sequencing, and point-of-care diagnostics are being implemented in clinical settings, improving the speed and accuracy of diagnoses for infectious and chronic diseases alike. Partnerships between global diagnostic manufacturers and local healthcare institutions are enhancing access to modern IVD platforms tailored to South Africa’s epidemiological profile.

Thus, the high prevalence of communicable and non-communicable diseases, government screening initiatives, and adoption of advanced testing technologies are key factors driving the market expansion in South Africa.

The US Food and Drug Administration, National Institute of Health, are among the primary and secondary sources referred to while preparing the Middle East & Africa in-vitro diagnostic market report.

Reasons to Buy

Saves and reduces time required for identifying the market growth, size, leading players, and segments in the Middle East & Africa In-Vitro Diagnostic market.
Highlights key business priorities to assist companies in realigning their business strategies
Emphasizes key findings and recommendations that uncover emerging industry trends in the Middle East & Africa In-Vitro Diagnostic market, enabling stakeholders across the value chain to craft effective long-term strategies
Develop/modify business expansion plans by analyzing substantial growth prospects in mature and emerging markets
Scrutinizes in-depth Middle East & Africa In-Vitro Diagnostic market trends, along with factors driving the market, as well as those hindering it
Enhances the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution Show more